Date: May 17, 2022
|
MEDIWOUND LTD.
By: /s/ Boaz Gur-Lavie
Name: Boaz Gur-Lavie
Title: Chief Financial Officer
|
Exhibit |
Description
|
99.1 |
99.2 |
• |
Total revenues for the first quarter of 2022 were $4.4 million compared to $5.8 million in the first quarter of 2021
|
• |
Raised an additional $10 million of total net proceeds through an equity offering
|
• |
Cash and short-term investments of $16.8 million as of March 31, 2022
|
• |
Positive results from its U.S. Phase 2 clinical study of EscharEx® for the debridement of venous leg ulcers (VLUs): (i) the study met its primary and its key secondary endpoints with statistically significant results compared
to control arms; (ii) significant improvement over the current standard-of-care; and (iii) no deleterious effects on wound closure and no observed safety issues.
|
• |
EscharEx clinical data from phase 2 clinical trials was highlighted in poster and oral presentation at the symposium of advance wound care (SAWC)
|
• |
The Biomedical Advanced Research and Development Authority (BARDA) expanded its awarded contract by providing supplemental funding of $9 million to support the NexoBrid BLA resubmission with the FDA and the ongoing expanded access
treatment protocol (NEXT)
|
• |
Awarded a U.S. Department of Defense (DoD) research grant for the development of NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army
|
Contacts:
Boaz Gur-Lavie
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com
|
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com
|
March 31,
|
December 31,
|
|||||||||||
2022
|
2021
|
2021
|
||||||||||
Un-audited
|
Audited
|
|||||||||||
Cash, cash equivalents and short-term deposits
|
16,836
|
17,862
|
11,046
|
|||||||||
Trade and other receivable
|
3,200
|
5,574
|
2,706
|
|||||||||
Inventories
|
1,920
|
1,470
|
1,200
|
|||||||||
Total current assets
|
21,956
|
24,906
|
14,952
|
|||||||||
Other receivables
|
230
|
-
|
469
|
|||||||||
Property, plant and equipment, net
|
2,471
|
2,694
|
2,478
|
|||||||||
Right of use assets, net
|
1,429
|
1,747
|
1,548
|
|||||||||
Intangible assets, net
|
281
|
347
|
297
|
|||||||||
Total non-current assets
|
4,411
|
4,788
|
4,792
|
|||||||||
Total assets
|
26,367
|
29,694
|
19,744
|
|||||||||
Current maturities of long-term liabilities
|
2,572
|
1,884
|
2,408
|
|||||||||
Trade payables and accrued expenses
|
5,623
|
3,258
|
4,693
|
|||||||||
Other payables
|
3,055
|
5,172
|
3,620
|
|||||||||
Total current liabilities
|
11,250
|
10,314
|
10,721
|
|||||||||
Deferred revenues
|
91
|
693
|
119
|
|||||||||
Liabilities in respect of IIA grants net of current maturities
|
7,897
|
7,275
|
7,885
|
|||||||||
Liabilities in respect of purchase of shares net of current maturities
|
3,642
|
4,733
|
3,992
|
|||||||||
Lease liabilities, net of current maturities
|
1,239
|
1,590
|
1,391
|
|||||||||
Severance pay liability, net
|
303
|
273
|
288
|
|||||||||
Total non-current liabilities
|
13,172
|
14,564
|
13,605
|
|||||||||
Shareholders' equity (deficit)
|
1,945
|
4,816
|
(4,582
|
)
|
||||||||
Total liabilities & shareholder equity
|
26,367
|
29,694
|
19,744
|
Three months ended
|
||||||||
March 31,
|
||||||||
2022
|
2021
|
|||||||
Revenues
|
4,407
|
5,847
|
||||||
Cost of revenues
|
2,947
|
3,431
|
||||||
Gross profit
|
1,460
|
2,416
|
||||||
Operating expenses:
|
||||||||
Research and development
|
2,408
|
2,242
|
||||||
Selling, general and administrative
|
2,336
|
2,095
|
||||||
Operating loss
|
(3,284
|
)
|
(1,921
|
)
|
||||
Financial expense, net
|
(301
|
)
|
(930
|
)
|
||||
Loss before taxes on income
|
(3,585
|
)
|
(2,851
|
)
|
||||
Taxes on income
|
(4
|
)
|
-
|
|||||
(3,589
|
)
|
(2,851
|
)
|
|||||
Foreign currency translation adjustments
|
5
|
11
|
||||||
Total comprehensive loss
|
(3,584
|
)
|
(2,840
|
)
|
||||
Basic and diluted loss per share:
|
||||||||
Net loss per share
|
(0.12
|
)
|
(0.10
|
)
|
||||
Weighted average number of ordinary shares used in the computation of basic and diluted loss per share:
|
28,733
|
27,237
|
Three months ended
|
||||||||
March 31,
|
||||||||
2022
|
2021
|
|||||||
Loss for the period
|
(3,589
|
)
|
(2,851
|
)
|
||||
Adjustments:
|
||||||||
Financial expenses, net
|
(301
|
)
|
(930
|
)
|
||||
Tax expenses
|
(4
|
)
|
-
|
|||||
Depreciation and amortization
|
(321
|
)
|
(273
|
)
|
||||
Share-based compensation expenses
|
(345
|
)
|
(384
|
)
|
||||
Total adjustments
|
(971
|
)
|
(1,587
|
)
|
||||
Adjusted EBITDA
|
(2,618
|
)
|
(1,264
|
)
|
Three months ended
|
||||||||
March 31,
|
||||||||
2021
|
2021
|
|||||||
Cash Flows from Operating Activities:
|
||||||||
Net loss
|
(3,589
|
)
|
(2,851
|
)
|
||||
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
|
||||||||
Adjustments to profit and loss items:
|
||||||||
Depreciation and amortization
|
321
|
273
|
||||||
Share-based compensation
|
345
|
384
|
||||||
Revaluation of liabilities in respect of IIA grants
|
234
|
275
|
||||||
Revaluation of liabilities in respect of purchase of shares
|
137
|
152
|
||||||
Revaluation of lease liabilities
|
(14
|
)
|
(44
|
)
|
||||
Increase (decrease) in severance liability, net
|
20
|
(10
|
)
|
|||||
Financing income
|
-
|
(11
|
)
|
|||||
Unrealized foreign currency loss
|
245
|
256
|
||||||
1,288
|
1,275
|
|||||||
Changes in asset and liability items:
|
||||||||
Increase in trade receivables
|
(579
|
)
|
(2,407
|
)
|
||||
Increase in inventories
|
(710
|
)
|
(45
|
)
|
||||
Decrease in other receivables
|
125
|
37
|
||||||
Increase in trade payables & accrued expenses
|
283
|
272
|
||||||
Increase (decrease) in other payables & deferred revenues
|
(883
|
)
|
806
|
|||||
(1,764
|
)
|
(1,337
|
)
|
|||||
Net cash used in operating activities
|
(4,065
|
)
|
(2,913
|
)
|
||||
Cash Flows from Investment Activities:
|
||||||||
Purchase of property and equipment
|
(160
|
)
|
(218
|
)
|
||||
Interest received
|
-
|
35
|
||||||
Proceeds from short term bank deposits
|
-
|
4,006
|
||||||
Net cash (used in) provided by investing activities
|
(160
|
)
|
3,823
|
|||||
Cash Flows from Financing Activities:
|
||||||||
Repayment of lease liabilities
|
(178
|
)
|
(131
|
)
|
||||
Repayment of IIA grants
|
(162
|
)
|
(180
|
)
|
||||
Proceeds from issue of share capital
|
10,417
|
-
|
||||||
Net cash used in financing activities
|
10,067
|
(311
|
)
|
|||||
Exchange rate differences on cash and cash equivalent balances
|
(247
|
)
|
(291
|
)
|
||||
Increase in cash and cash equivalents
|
5,605
|
308
|
||||||
Balance of cash and cash equivalents at the beginning of the period
|
11,046
|
17,376
|
||||||
Balance of cash and cash equivalents at the end of the period
|
16,651
|
17,684
|
Page
|
|
F-2
|
|
F-3
|
|
F-4
|
|
F-5 – F-6
|
|
F-7 – F-9
|
March 31,
|
December 31,
|
|||||||||||
2022
|
2021
|
2021
|
||||||||||
Unaudited
|
Audited
|
|||||||||||
Cash and cash equivalents
|
16,651
|
17,684
|
11,046
|
|||||||||
Restricted deposits
|
185
|
178
|
-
|
|||||||||
Trade receivables
|
2,348
|
5,153
|
1,779
|
|||||||||
Inventories
|
1,920
|
1,470
|
1,200
|
|||||||||
Other receivables
|
852
|
421
|
927
|
|||||||||
Total current assets
|
21,956
|
24,906
|
14,952
|
|||||||||
Other receivables
|
230
|
-
|
469
|
|||||||||
Property, plant and equipment, net
|
2,471
|
2,694
|
2,478
|
|||||||||
Right of-use assets, net
|
1,429
|
1,747
|
1,548
|
|||||||||
Intangible assets, net
|
281
|
347
|
297
|
|||||||||
Total non-current assets
|
4,411
|
4,788
|
4,792
|
|||||||||
Total assets
|
26,367
|
29,694
|
19,744
|
|||||||||
Current maturities of long-term liabilities
|
2,572
|
1,884
|
2,408
|
|||||||||
Trade payables and accrued expenses
|
5,623
|
3,258
|
4,693
|
|||||||||
Other payables
|
3,055
|
5,172
|
3,620
|
|||||||||
Total current liabilities
|
11,250
|
10,314
|
10,721
|
|||||||||
Deferred revenues
|
91
|
693
|
119
|
|||||||||
Liabilities in respect of IIA grants
|
7,897
|
7,275
|
7,885
|
|||||||||
Liabilities in respect of purchase of shares
|
3,642
|
4,733
|
3,922
|
|||||||||
Lease liabilities
|
1,239
|
1,590
|
1,391
|
|||||||||
Severance pay liability, net
|
303
|
273
|
288
|
|||||||||
Total non-current liabilities
|
13,172
|
14,564
|
13,605
|
|||||||||
Total liabilities
|
24,422
|
24,878
|
24,326
|
|||||||||
Shareholders' equity:
|
||||||||||||
Ordinary shares of NIS 0.01 par value:
|
||||||||||||
Authorized: 50,000,000 shares as of March 31, 2022, December 31, 2021 and March 31, 2021; Issued and Outstanding: 33,140,633 as of March 31, 2022, 27,272,818 as of December 31, 2021 and : 27,245,271 as of March 31, 2021
|
93
|
75
|
75
|
|||||||||
Share premium
|
153,962
|
142,577
|
143,869
|
|||||||||
Foreign currency translation reserve
|
(14
|
)
|
(29
|
)
|
(19
|
)
|
||||||
Accumulated deficit
|
(152,096
|
)
|
(137,807
|
)
|
(148,507
|
)
|
||||||
Total equity (deficit)
|
1,945
|
4,816
|
(4,582
|
)
|
||||||||
Total liabilities and equity
|
26,367
|
29,694
|
19,744
|
Three months ended
March 31,
|
Year ended
December 31,
|
|||||||||||
2022
|
2021
|
2021
|
||||||||||
Unaudited
|
Audited
|
|||||||||||
Revenues from sale of products
|
1,102
|
2,518
|
9,613
|
|||||||||
Revenues from development services
|
3,089
|
2,940
|
12,372
|
|||||||||
Revenues from license agreements
|
216
|
389
|
1,778
|
|||||||||
Total revenues
|
4,407
|
5,847
|
23,763
|
|||||||||
Cost of revenues from sale of products
|
391
|
1,140
|
4,983
|
|||||||||
Cost of revenues from development services
|
2,541
|
2,273
|
9,907
|
|||||||||
Cost of revenues from license agreements
|
15
|
18
|
102
|
|||||||||
Total cost of revenues
|
2,947
|
3,431
|
14,992
|
|||||||||
Gross profit
|
1,460
|
2,416
|
8,771
|
|||||||||
Research and development
|
2,408
|
2,242
|
10,256
|
|||||||||
Selling and marketing
|
919
|
822
|
3,388
|
|||||||||
General and administrative
|
1,417
|
1,273
|
6,348
|
|||||||||
Total operating expenses
|
4,744
|
4,337
|
19,992
|
|||||||||
Operating loss
|
(3,284
|
)
|
(1,921
|
)
|
(11,221
|
)
|
||||||
Financial income
|
139
|
11
|
11
|
|||||||||
Financial expense
|
(440
|
)
|
(941
|
)
|
(2,314
|
)
|
||||||
Financing expenses, net
|
(301
|
)
|
(930
|
)
|
(2,303
|
)
|
||||||
Loss before taxes on income
|
(3,585
|
)
|
(2,851
|
)
|
(13,524
|
)
|
||||||
Taxes on income
|
(4
|
)
|
-
|
(27
|
)
|
|||||||
Net loss
|
(3,589
|
)
|
(2,851
|
)
|
(13,551
|
)
|
||||||
Other comprehensive income :
|
||||||||||||
Foreign currency translation adjustments
|
5
|
11
|
21
|
|||||||||
Total comprehensive loss
|
(3,584
|
)
|
(2,840
|
)
|
(13,530
|
)
|
||||||
Loss per share data
|
||||||||||||
Basic and diluted net loss per share - USD
|
(0.12
|
)
|
(0.10
|
)
|
(0.50
|
)
|
||||||
Number of shares used in calculating basic and diluted net loss per share
|
28,733,130
|
27,236,876
|
27,244,475
|
Share capital
|
Share premium
|
Foreign currency translation reserve
|
Accumulated
deficit
|
Total
equity (deficit)
|
||||||||||||||||
Balance as of December 31, 2021
|
75
|
143,869
|
(19
|
)
|
(148,507
|
)
|
(4,582
|
)
|
||||||||||||
Loss for the period
|
-
|
-
|
-
|
(3,589
|
)
|
(3,589
|
)
|
|||||||||||||
Other comprehensive income
|
-
|
-
|
5
|
-
|
5
|
|||||||||||||||
Total comprehensive income (loss)
|
-
|
-
|
5
|
(3,589
|
) |
(3,584
|
)
|
|||||||||||||
Issue of ordinary shares
|
18
|
9,748
|
-
|
-
|
9,766
|
|||||||||||||||
Exercise of options
|
(*
|
)
|
(*
|
)
|
-
|
-
|
(*
|
)
|
||||||||||||
Share-based compensation
|
-
|
345
|
-
|
-
|
345
|
|||||||||||||||
Balance as of March 31, 2022
|
93
|
153,962
|
(14
|
)
|
(152,096
|
)
|
1,945
|
|||||||||||||
Balance as of December 31, 2020
|
75
|
142,193
|
(40
|
)
|
(134,956
|
)
|
7,272
|
|||||||||||||
Loss for the period
|
-
|
-
|
-
|
(2,851
|
)
|
(2,851
|
)
|
|||||||||||||
Other comprehensive income
|
-
|
-
|
11
|
-
|
11
|
|||||||||||||||
Total comprehensive income (loss)
|
-
|
-
|
11
|
(2,851
|
)
|
(2,840
|
)
|
|||||||||||||
Exercise of options and RSU’s
|
(*
|
)
|
(*
|
)
|
-
|
-
|
(*
|
)
|
||||||||||||
Share-based compensation
|
-
|
384
|
-
|
-
|
384
|
|||||||||||||||
Balance as of March 31, 2021
|
75
|
142,577
|
(29
|
)
|
(137,807
|
)
|
4,816
|
|||||||||||||
Balance as of December 31, 2020
|
75
|
142,193
|
(40
|
)
|
(134,956
|
)
|
7,272
|
|||||||||||||
Loss for the period
|
-
|
-
|
-
|
(13,551
|
)
|
(13,551
|
)
|
|||||||||||||
Other comprehensive income
|
-
|
-
|
21
|
-
|
21
|
|||||||||||||||
Total comprehensive income (loss)
|
- |
- |
21 |
(13,551 |
) |
(13,530
|
) |
|||||||||||||
Exercise of options
|
(*
|
)
|
3
|
-
|
-
|
3
|
||||||||||||||
Share-based compensation
|
-
|
1,673
|
-
|
-
|
1,673
|
|||||||||||||||
Balance as of December 31, 2021
|
75
|
143,869
|
(19
|
)
|
(148,507
|
)
|
(4,582
|
)
|
Three months ended
March 31,
|
Year ended
December 31,
|
|||||||||||
2022
|
2021
|
2021
|
||||||||||
Unaudited
|
Audited
|
|||||||||||
Cash Flows from Operating Activities:
|
||||||||||||
Net loss
|
(3,589
|
)
|
(2,851
|
)
|
(13,551
|
)
|
||||||
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
|
||||||||||||
Adjustments to profit and loss items:
|
||||||||||||
Depreciation and amortization
|
321
|
273
|
1,238
|
|||||||||
Share-based compensation
|
345
|
384
|
1,673
|
|||||||||
Revaluation of liabilities in respect of IIA grants
|
234
|
275
|
919
|
|||||||||
Revaluation of liabilities in respect of purchase of shares
|
137
|
152
|
590
|
|||||||||
Revaluation of lease liabilities
|
(14
|
)
|
(44
|
)
|
188
|
|||||||
Increase (decrease) in severance pay liability, net
|
20
|
(10
|
)
|
13
|
||||||||
Net financing income
|
-
|
(11
|
)
|
(11
|
)
|
|||||||
Un-realized foreign currency (gain) loss
|
245
|
256
|
(137
|
)
|
||||||||
1,288
|
1,275
|
4,473
|
||||||||||
Changes in asset and liability items:
|
||||||||||||
Decrease (increase) in trade receivables
|
(579
|
)
|
(2,407
|
)
|
929
|
|||||||
Decrease (increase) in inventories
|
(710
|
)
|
(45
|
)
|
257
|
|||||||
Decrease (increase) in other receivables
|
125
|
37
|
(763
|
)
|
||||||||
Increase in trade payables and accrued expenses
|
283
|
272
|
1,723
|
|||||||||
Increase (decrease) in other payables and deferred revenues
|
(883
|
)
|
806
|
(1,984
|
)
|
|||||||
(1,764
|
)
|
(1,337
|
)
|
162
|
||||||||
Net cash used in operating activities
|
(4,065
|
)
|
(2,913
|
)
|
(8,916
|
)
|
Three months ended
March 31,
|
Year ended
December 31,
|
|||||||||||
2022
|
2021
|
2021
|
||||||||||
Unaudited
|
Audited
|
|||||||||||
Cash Flows from Investing Activities:
|
||||||||||||
Purchase of property and equipment
|
(160
|
)
|
(218
|
)
|
(489
|
)
|
||||||
Interest received
|
-
|
35
|
35
|
|||||||||
Proceeds from short term bank deposits, net
|
-
|
4,006
|
4,002
|
|||||||||
Net cash (used in) provided by investing activities
|
(160
|
)
|
3,823
|
3,548
|
||||||||
Cash Flows from Financing Activities:
|
||||||||||||
Repayment of leases liabilities
|
(178
|
)
|
(131
|
)
|
(693
|
)
|
||||||
Proceeds from issuance of shares, net
|
10,417
|
-
|
3
|
|||||||||
Repayment of IIA grants, net
|
(162
|
)
|
(180
|
)
|
(360
|
)
|
||||||
Net cash provided by (used in) financing activities
|
10,077
|
(311
|
)
|
(1,050
|
)
|
|||||||
Exchange rate differences on cash and cash equivalent balances
|
(247
|
)
|
(291
|
)
|
88
|
|||||||
Increase (decrease) in cash and cash equivalents
|
5,605
|
308
|
(6,330
|
)
|
||||||||
Balance of cash and cash equivalents at the beginning of the period
|
11,046
|
17,376
|
17,376
|
|||||||||
Balance of cash and cash equivalents at the end of the period
|
16,651
|
17,684
|
11,046
|
|||||||||
Supplement disclosure of Non-cash transactions:
|
||||||||||||
ROU asset, net recognized with corresponding lease liability
|
-
|
-
|
155
|
|||||||||
Exercise of RSU’s
|
177
|
43
|
147
|
Note 1: |
GENERAL
|
a. |
Description of the Company and its operations:
|
b. |
The Company's securities are listed for trading on NASDAQ since March 2014. In March, 2022, the Company completed a public offering. A total of 5,208,333 new ordinary shares were issued at a public offering price of $1.92 per share. The
gross proceeds before deducting underwriting discounts and commissions and offering expenses, were approximately $10 million. (see also Note 3).
|
c. |
The Company has three wholly owned subsidiaries: MediWound Germany GmbH, acting as Europe (“EU”) marketing authorization holder and EU sales and marketing arm, MediWound UK Limited and MediWound US, Inc. are currently inactive companies.
|
Note 1: |
GENERAL (Cont.)
|
d. |
The Company awarded two contracts with the U.S. Biomedical Advanced Research and Development Authority ("BARDA") valued at up to $168,000 for the advancement of the development, manufacturing and emergency readiness for NexoBrid deployment
as well as the procurement of NexoBrid as a medical countermeasure as part of BARDA preparedness for mass casualty events. In February 2022 BARDA has expanded its awarded contract providing supplemental funding of approximately $9,000 to
support the NexoBrid BLA resubmission to the FDA and the continuous expanded access program.
|
e. |
On February 17, 2022 the Company engaged with the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), for a $1.7 million contract for the development of NexoBrid as a non-surgical solution for
field-care burn treatment for the U.S. Army.
|
f. |
On June 29, 2021, the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) seeking approval of NexoBrid for eschar removal (debridement) in
adults with deep partial-thickness and/or full-thickness thermal burns.
|
g. |
The Company addresses the challenges associated with the ongoing COVID-19 pandemic, while prioritizing the health and safety of its workforce and maintaining operational efficiency and flexibility.
|
NOTE 2: |
SIGNIFICANT ACCOUNTING POLICIES
|
a. |
Basis of presentation of financial statements:
|
b. |
Basis of preparation of the interim consolidated financial statements:
|
NOTE 2: |
EQUITY
|